Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharm Holdings (NQ: TNXP )

0.1678 +0.0078 (+4.88%)
Streaming Delayed Price Updated: 1:51 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tonix Pharm Holdings

New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
Via AB Newswire
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Via ACCESSWIRE
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
Via ACCESSWIRE
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
Via ACCESSWIRE
New Hope for Long COVID Sufferers
Via ACCESSWIRE
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US
Via ACCESSWIRE
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
Via Get News
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Via ACCESSWIRE
Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences
Via ACCESSWIRE
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations
by Faith Ashmore - Benzinga 
Via TheNewswire.com
Exposures COVID-19
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Exposures Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
Psychedelics Use Among Young Adults Reaches All-Time High
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
Via FinancialNewsMedia
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Via FinancialNewsMedia
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia
Exposures COVID-19
Global Market For Sleep Aid Devices Could Reach $112.7 Billion By 2025
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.